{
  "id": 18640972,
  "title": "Martine Rothblatt, United Therapeutics CEO, sells $4.3M in shares",
  "url": "https://urgent.news/2026/11/07/martine-rothblatt-united-therapeutics-ceo-sells-4-3m-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-07T05:01:45.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/martine-rothblatt-united-therapeutics-ceo-sells-43m-in-shares-93CH-5009650"
  },
  "original_language": "en",
  "account": "Martine A. Rothblatt, CEO of United Therapeutics Corp (NASDAQ: UTHR), sold a significant number of shares on November 5, 2026, for approximately $4.33 million. The shares were sold in increments, ranging in price from $562.18 to $591.84, and were part of a pre-arranged trading plan she established in November 2025. This sale took place as United Therapeutics' stock price hovered around $562, having increased by 25% over the previous year. However, experts suggest that the shares might be overvalued at their current price point.\n\nIn addition to the share sale, Rothblatt also exercised options to purchase 9,500 shares at an exercise price of $117.76 per share, which amounted to about $1.12 million. These options had been vested in tranches on March 15, 2021, 2022, and 2023, as part of the same trading plan. After these transactions, she directly owns 40,513 shares of United Therapeutics common stock. Furthermore, Rothblatt maintains a diverse investment portfolio, including indirect holdings in family trusts. These include 326,403 shares, 166 shares, 249,108 shares, 45,596 shares, and 8,902 shares, held in trusts where she or her spouse serves as trustee or settlor, as well as 81,410 stock options indirectly held in a family trust. All of these holdings were reported in a Form 4 filing dated November 6, 2026.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}